共 50 条
- [41] A prospective, single-arm, open-label, phase II clinical trial on efficacy and safety of cadonilimab plus anlotinib for recurrent, metastatic or persistent cervical cancerGYNECOLOGIC ONCOLOGY, 2024, 190 : S290 - S290Yang, ChunxuSun, ShaoxingXiang, QingmingChen, MinMei, ZijieWu, QiujiQiu, Hui
- [42] Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trialLANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (03): : 209 - 217Kawazoe, AkihitoAndo, TakayukiHosaka, HisashiFujita, JunyaKoeda, KeisukeNishikawa, KazuhiroAmagai, KenjiFujitani, KazumasaOgata, KazuhiroWatanabe, KeitaYamamoto, YujiShitara, Kohei
- [44] EV-202: An open-label, multicenter, phase 2 study of enfortumab vedotin in patients with previously treated locally advanced or metastatic solid tumors, including multiple gastroesophageal cancer cohortsANNALS OF ONCOLOGY, 2022, 33 : S298 - S298Muro, K.Bruce, J. YangBaranda, J.Campbell, M.Wu, C.Gorla, S.Braiteh, F.
- [45] Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Wu, XiaohuaXia, LingfangZhou, QiZhu, JianqingWang, KeChen, JieHuang, YiKurb, GulinaChang, BaopingZhao, WeidongWang, XiaYang, YingjieLin, ZhongqiuLuo, XiaoyongLou, GeWang, ChunyanWang, JingMeng, Haijin
- [46] Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER TrialCLINICAL COLORECTAL CANCER, 2020, 19 (04) : 270 - 276Piccirillo, Maria CarmelaAvallone, AntonioCarlomagno, ChiaraMaiello, EvaristoRosati, GerardoAlabiso, OscarNasti, GuglielmoDe Placido, SabinoLatiano, Tizana PiaBilancia, DomenicoOttaiano, AlessandroDe Stefano, AlfonsoRomano, CarmelaSilvestro, LucreziaNappi, AnnaCassata, AntoninoGiordano, PasqualinaIaffaioli, Rosario VincenzoNormanno, NicolaPerrone, FrancescoDaniele, Bruno
- [47] Inetetamab combined with pyrotinib and Chemotherapy in Pretreated Patients with HER2-positive metastatic breast cancer, a single arm, multicenter phase II clinical trialCANCER RESEARCH, 2023, 83 (05)Zhao, JianliCai, YangyangDing, LinxiaoxiaoYang, YapingZou, GuorongYao, HeruiWang, Ying
- [48] Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trialECLINICALMEDICINE, 2025, 80Guchelaar, Niels A. D.Mathijssen, Ron H. J.de Boer, Maaikevan Bekkum, Marlies L.Heijns, Joan B.Vriens, Birgit E. P. J.van Rosmalen, Mandy M.Kessels, Lonneke W.Hamming, LisanneBeelen, Karin J.Nieboer, Petervan den Berg, Susan M.Oomen-de Hoop, EstherBijlsma, Rhode M.Bos, Monique E. M. M.
- [49] AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)Wu, LingyingWang, Peng-HuiHsiao, Sheng-YenChang, Chih-LongKim, Hee SeungLee, Jung-YunRyu, Sang-YoungZuo, YunxiaMu, XiyanGao, YujuanYang, SiluLee, Jae-Kwan
- [50] Evaluation of the effectiveness and safety of disitamab vedotin for HER2-expressing recurrent cervical cancer after progression on platinum-based treatment-a single-arm, multicenter, open-label, phase II clinical studyINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A6 - A6Wu, LingyingLi, GuilingZhang, YouzhongAn, RuifangSun, LiZhang, KeqiangHuang, YiGuo, RuixiaLi, QingshuiMiao, JinweiLin, AnYuan, JianlinLou, GeYang, HongyingZhang, YuZhang, HuiHe, AiqinTang, JunyingYing, JianmingLing, YunFang, Jianmin